Heart & lung : the journal of critical care · 2026
Impaired hemostasis in mechanical circulatory support systems: Monitoring with T-TAS® 01, in vitro correction with VWF concentrates, and impact of membrane oxygenators.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Escribano-Serrat Silvia, Moreno-Castaño Ana Belén, Pino Marc, de la Torre Mariano, Koller Tobias, García Estefanía, Martín Lidia, Molina Patricia, De Moner Blanca, Ramos Álex, Téllez Adrián, Martinez-Sanchez Julia, Escolar Ginés, Castro Pedro, Sandoval Elena, Díaz-Ricart Maribel
Аннотация
BACKGROUND: Mechanical circulatory support (MCS) systems assist patients with severe cardiac or respiratory failure, but bleeding linked to acquired von Willebrand disease remains a major complication. The T-TAS® 01 system has emerged as a rapid tool for assessing MCS patients' hemostasis.
OBJECTIVES: To evaluate hemostatic changes during and after MCS support. Secondary objectives included assessing the impact of the in vitro addition of von Willebrand factor concentrates and exploring differences according to the presence of a membrane oxygenator (MO).
METHODS: This prospective, bicentric study included adults requiring MCS, with hemostatic parameters assessed at three predefined timepoints using conventional laboratory assays and T-TAS® 01. Data were analyzed using linear mixed-effects models. In vitro addition of a VWF/FVIII concentrate (Haemate-P®) was evaluated as an exploratory analysis.
RESULTS: A total of 39 patients were included; 56% experienced bleeding complications, of which 23% were clinically relevant. Significant alterations in hemoglobin, platelet counts, and platelet/VWF function were observed during MCS. T-TAS® 01 demonstrated impaired hemostasis during support, with partial recovery after device removal. In vitro addition of Haemate-P® improved T-TAS® 01 parameters. No consistent differences in overall hemostatic dynamics were observed between MO and non-MO devices.
CONCLUSION: MCS is associated with significant and persistent alterations in primary hemostasis. T-TAS® 01 may represent a useful tool for dynamic assessment of these changes. In vitro VWF supplementation improved functional hemostasis parameters, although its clinical implications remain to be established. Differences related to MO presence were not consistent, supporting a shared mechanism of hemostatic dysregulation across MCS devices.
OBJECTIVES: To evaluate hemostatic changes during and after MCS support. Secondary objectives included assessing the impact of the in vitro addition of von Willebrand factor concentrates and exploring differences according to the presence of a membrane oxygenator (MO).
METHODS: This prospective, bicentric study included adults requiring MCS, with hemostatic parameters assessed at three predefined timepoints using conventional laboratory assays and T-TAS® 01. Data were analyzed using linear mixed-effects models. In vitro addition of a VWF/FVIII concentrate (Haemate-P®) was evaluated as an exploratory analysis.
RESULTS: A total of 39 patients were included; 56% experienced bleeding complications, of which 23% were clinically relevant. Significant alterations in hemoglobin, platelet counts, and platelet/VWF function were observed during MCS. T-TAS® 01 demonstrated impaired hemostasis during support, with partial recovery after device removal. In vitro addition of Haemate-P® improved T-TAS® 01 parameters. No consistent differences in overall hemostatic dynamics were observed between MO and non-MO devices.
CONCLUSION: MCS is associated with significant and persistent alterations in primary hemostasis. T-TAS® 01 may represent a useful tool for dynamic assessment of these changes. In vitro VWF supplementation improved functional hemostasis parameters, although its clinical implications remain to be established. Differences related to MO presence were not consistent, supporting a shared mechanism of hemostatic dysregulation across MCS devices.